Literature DB >> 31354205

Pathogenesis of Uveitic Glaucoma.

Dimitrios Kalogeropoulos1, Velota Ct Sung1.   

Abstract

Uveitic glaucoma consists one of the most serious complications of intraocular inflammation and, despite its rarity, is considered as one of the leading causes of preventable loss of vision worldwide. It has been associated with a wide spectrum of inflammatory diseases, but its pathogenesis is still not fully comprehended. It appears that the type of inflammation, the steroid-response and the anatomical alterations of the anterior chamber play a pivotal role. To our knowledge, the mechanisms may be both acute and chronic. The main targets of the treatment are to control the inflammation and reduce the intraocular pressure (IOP). The management of glaucoma associated with uveitis remains an extremely challenging condition for ophthalmologists. The successful treatment of uveitic glaucoma is inextricably correlated with prompt and immediate therapeutic decisions. Very often a solid collaboration between clinicians from different specialties may be required for treating the underlying disease. Further understanding of its pathogenesis can indicate therapeutic targets and may lead to the development of new and more efficient therapeutic approaches. New glaucoma surgical modalities may ameliorate the prognosis after surgical intervention, but this calls for further evaluation. This study aims to highlight the complexity of uveitic glaucoma analyzing the main pathogenetic mechanisms and the correlations with the inflammatory response. HOW TO CITE THIS ARTICLE: Kalogeropoulos D, Sung VCT. Pathogenesis of Uveitic Glaucoma. J Curr Glaucoma Pract 2018;12(3):125-138.

Entities:  

Keywords:  Glaucoma; Intraocular pressure; Ocular hypertension/hypotony; Ocular inflammation; Uveitic glaucoma; Uveitis

Year:  2018        PMID: 31354205      PMCID: PMC6647826          DOI: 10.5005/jp-journals-10028-1257

Source DB:  PubMed          Journal:  J Curr Glaucoma Pract        ISSN: 0974-0333


  150 in total

1.  Aqueous humor dynamics in the aging human eye.

Authors:  C B Toris; M E Yablonski; Y L Wang; C B Camras
Journal:  Am J Ophthalmol       Date:  1999-04       Impact factor: 5.258

2.  Latanoprost 0.005% and anterior segment uveitis.

Authors:  S L Smith; C A Pruitt; C S Sine; A C Hudgins; W C Stewart
Journal:  Acta Ophthalmol Scand       Date:  1999-12

Review 3.  Free radical mediated photoreceptor damage in uveitis.

Authors:  N A Rao; G S Wu
Journal:  Prog Retin Eye Res       Date:  2000-01       Impact factor: 21.198

Review 4.  Classification of herpes simplex virus keratitis and anterior uveitis.

Authors:  T J Liesegang
Journal:  Cornea       Date:  1999-03       Impact factor: 2.651

5.  Long-term follow-up of trabeculectomy without antimetabolites in patients with uveitis.

Authors:  P Stavrou; P I Murray
Journal:  Am J Ophthalmol       Date:  1999-10       Impact factor: 5.258

6.  Management of uveitic glaucoma with Ahmed glaucoma valve implantation.

Authors:  A Da Mata; S E Burk; P A Netland; S Baltatzis; W Christen; C S Foster
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

7.  Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit.

Authors:  H E Kaufman; E D Varnell; H W Thompson
Journal:  Am J Ophthalmol       Date:  1999-05       Impact factor: 5.258

8.  Latanoprost and herpes simplex keratitis.

Authors:  M Wand; C M Gilbert; T J Liesegang
Journal:  Am J Ophthalmol       Date:  1999-05       Impact factor: 5.258

9.  Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma.

Authors:  G B Shah; S Sharma; A A Mehta; R K Goyal
Journal:  J Cardiovasc Pharmacol       Date:  2000-08       Impact factor: 3.105

10.  Molecular analysis of resolving immune responses in uveitis.

Authors:  P I Murray; C D Clay; C Mappin; M Salmon
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

View more
  8 in total

1.  Aetiology and clinical characteristics of uveitic glaucoma in Turkish patients.

Authors:  Cigdem Altan; Berna Basarir
Journal:  Int Ophthalmol       Date:  2021-03-17       Impact factor: 2.031

Review 2.  Pathogenesis and Manifestations of Zika Virus-Associated Ocular Diseases.

Authors:  Bisant A Labib; DeGaulle I Chigbu
Journal:  Trop Med Infect Dis       Date:  2022-06-15

3.  Elevation of Tear MMP-9 Concentration as a Biomarker of Inflammation in Ocular Pathology by Antibody Microarray Immunodetection Assays.

Authors:  Miguel de la Fuente; Iñaki Rodríguez-Agirretxe; Elena Vecino; Egoitz Astigarraga; Arantxa Acera; Gabriel Barreda-Gómez
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

Review 4.  Tissue-Engineered Models for Glaucoma Research.

Authors:  Renhao Lu; Paul A Soden; Esak Lee
Journal:  Micromachines (Basel)       Date:  2020-06-24       Impact factor: 2.891

5.  The Effect of Perioperative Uveitis Control on the Success of Glaucoma Surgery in Uveitic Glaucoma.

Authors:  Moustafa S Magliyah; Abdulrahman H Badawi; Abdulaziz A Alshamrani; Rizwan Malik; Hassan Al-Dhibi
Journal:  Clin Ophthalmol       Date:  2021-04-09

Review 6.  Nanotechnology-based formulations to amplify intraocular bioavailability.

Authors:  Konstantinos Kagkelaris; George Panayiotakopoulos; Constantinos D Georgakopoulos
Journal:  Ther Adv Ophthalmol       Date:  2022-07-18

7.  Mechanism of Secondary Glaucoma Development in HTLV-1 Uveitis.

Authors:  Yuan Zong; Koju Kamoi; Naoko Ando; Hisako Kurozumi-Karube; Kyoko Ohno-Matsui
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

8.  The Management of Uveitic Glaucoma in Children

Authors:  Dimitrios Kalogeropoulos; Christos Kalogeropoulos; Marilita M. Moschos; Velota Sung
Journal:  Turk J Ophthalmol       Date:  2019-10-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.